Newer type 2 diabetes drugs show heart protective quality in study

By Bill Berkrot
| WASHINGTON

ADVERTISEMENT

WASHINGTON A newer class of type 2 diabetes drugs significantly cut the risk of death and hospitalization for heart failure compared with other medicines for the disease, according to data released on Sunday from a so-called real world study sponsored by AstraZeneca.

The drugs, known as SGLT-2 inhibitors, work by removing blood sugar via the urine and include Astra’s Farxiga, Jardiance from Eli Lilly and Co and Boehringer Ingelheim, and Invokana from Johnson & Johnson.

Jardiance caused a stir in 2015, when a clinical trial conducted to reassure it does not cause heart problems instead showed it reduced the combined risk of hospitalization for heart failure or death from heart failure by 39 percent in high risk patients. The heart benefit has since been incorporated into Jardiance’s label.

AstraZeneca is conducting its own large clinical trials to determine the heart effect of Farxiga with results expected in 2019.

But the latest data presented by Dr. Mikhail Kosiborod at the American College of Cardiology scientific meeting in Washington appears to indicate that heart protection is not limited to Jardiance.

“The fact that the results are remarkably consistent from country to country regardless of which compound predominates, that certainly seems to suggest that it’s a class effect,” said Kosiborod, a cardiologist from Saint Luke’s Mid America Heart Institute in Kansas City. He noted that most Americans in the data were taking Invokana, while Farxiga was dominant in Europe.

The study, which analyzed data from more than 300,000 type 2 diabetes patients collected from six countries, found the SGLT-2 drugs slashed the combined risk of hospitalization for heart failure and death from any cause by 46 percent.

The data was obtained from real-world sources, such as medical records, claims databases and national registers.

Most patients were taking Farxiga or Invokana with less than 10 percent on Jardiance. The comparator medicines included a wide variety of diabetes treatments, including metformin, DPP-4 inhibitors, such as Merck & Co’s Januvia, and insulin, among others.

The vast majority of patients had no history of heart disease. But heart disease is the number one killer of people with diabetes, and mounting evidence of heart protective qualities of SGLT-2 drugs could lead to greater use.

“This class has a real potential of improving patient outcomes,” Kosiborod said.

Given the observational nature of the study the possibility of unmeasured confounding factors exists, researchers noted.

More than 400 million people worldwide have diabetes, of whom at least 90 percent have type 2.

(This story has been refiled to add word in last paragraph)

(Reporting by Bill Berkrot; Editing by Phil Berlowitz)

-Reuters


Notice an issue?

Arabian Post strives to deliver the most accurate and reliable information to its readers. If you believe you have identified an error or inconsistency in this article, please don't hesitate to contact our editorial team at editor[at]thearabianpost[dot]com. We are committed to promptly addressing any concerns and ensuring the highest level of journalistic integrity.


ADVERTISEMENT
Just in:
CGTN: Beauty in diversity: How wisdom at Nishan Forum inspires global modernization // IIT Delhi and TeamLease EdTech Kick‑start AI for Healthcare Executive Programme // Galaxy AI Elevates On‑Device Intelligence with Privacy at Core // Meta pixel ruling marks watershed in EU data privacy // Tokyo Real Estate Set for $75 Million Blockchain Shake‑Up // Uweb, the Digital Asset Education Institute, Announces Successful Completion of a US$3 million Angel Funding Round // Coffee Chains Join Bitcoin Mania with Bold Treasury Moves // Baku ID 2025 Concludes: Baku Becomes the Regional Hub for Innovation // Entrepreneurs Turn to Harsh AI ‘Red Teamers’ to Stress‑Test Ideas // Can India Emerge As The Trusted Leader Of Global South Like Earlier Years? // Moroccan‐Born Duo Secures $4.2 Million to Sharpen AI Search Precision // Dong Yuhui’s Fujian Journey: The Sea’s Lesson – 30% Destiny, 70% Determination // Qingzhen’s Zhanjie Town Leverages Ecological Resources to Drive Industrial Upgrading and Integrate Culture and Tourism for Rural Revitalization // Behomes Launches Behomes Hub – Cashback & Networking App for Real Estate Professionals // MCP Ignites AI Agent Revolution Amid Looming Security Quagmire // Aramco Eyes New U.S. LNG Offtake in Cameron Deal // UAE Championing Balanced Oil Markets Through OPEC+ Engagement // MENA Investment Banking Fees Slip Amid Equity Underwriting Lull // Caltex Commemorates SG60 with Launch of Limited Edition National Day Picnic Sets // UAE Tightens Entry Rules for Nigerian Travellers //